Growth Hormone Axis Peptides: Research Applications

The Growth Hormone Axis

The growth hormone (GH) axis refers to the regulatory chain running from the hypothalamus (which secretes growth-hormone-releasing hormone, GHRH, and somatostatin) to the anterior pituitary (which secretes GH in response) to the liver and peripheral tissues (where GH stimulates IGF-1 production). Research peptides in this category are studied for their ability to modulate specific points along this axis, rather than supplying exogenous growth hormone directly.

Two Distinct Mechanisms

Peptides in this category generally fall into two mechanistic classes:

GHRH receptor agonists mimic the natural hypothalamic signal to the pituitary. CJC-1295 (no DAC) and Tesamorelin both fall into this class — modified analogs of GHRH(1-29) and GHRH(1-44) respectively, engineered for improved resistance to enzymatic degradation relative to the native hormone.

Ghrelin receptor agonists (GH secretagogues) act through a separate receptor (GHS-R1a) that also stimulates GH release, often with a more selective profile. Ipamorelin is studied as a selective secretagogue in this class, with research literature reporting minimal cross-reactivity with cortisol and prolactin pathways relative to earlier secretagogues.

Why Researchers Study Combinations

Because GHRH agonists and ghrelin-receptor agonists act on different receptors, preclinical research has frequently examined combination protocols (e.g., a GHRH analog paired with a ghrelin-receptor agonist) to study synergistic effects on GH pulse amplitude — a research question distinct from either compound’s effect in isolation.

Research Focus Areas

Across this category, published preclinical and clinical research has focused on:

• Pulsatile GH secretion dynamics and receptor pharmacology
• Downstream IGF-1 production and its relationship to metabolic markers
• Body composition and lipid metabolism research (most extensively documented for Tesamorelin)
• Comparative pharmacokinetics between short-acting and modified long-acting analogs

Related Reading

See individual product pages for CJC-1295 (no DAC), Ipamorelin, and Tesamorelin for compound-specific specifications, sequence data, and references. For general peptide handling, see Peptide Fundamentals and Storage & Handling.

This article summarizes published preclinical and clinical research literature. It does not constitute dosing or administration guidance. Peptide Factory products are supplied for research use only — not for human consumption.